Company / Interest Expense
Arcutis Biotherapeutics, Inc. Interest Expense History
FY2020-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Interest Expense
$29.7M
FY2023
5-year range
$0 / $29.7M
FY2020-FY2023
Trend
+89.8%
vs FY2022
Sector context
#17 of 44
Health Care
What the data says
At $30M, Arcutis Biotherapeutics, Inc.'s interest expense ranks #28 of 44 in the Health Care sector. Increased from $0 to $30M over the past 2 years.
Based on SEC 10-K filings.
$30M in FY2023.
Increased from $0 to $30M over the past 2 years.
Health Care sector context is included.
Interest Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#28 of 44 in Health CareTop 61% of 44This company $29.7M Sector average $291.0M
▼
-89.8% below sector average
Key checks
Key Insights
- In FY2023, interest expense increased 89.8% year-over-year.
- Ranks #17 out of 44 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -0.65 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Interest ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $29.7M | +89.8% |
| FY2022 | $15.7M | - |
| FY2021 | $0 | - |
| FY2020 | $0 | - |
| FY2019 | - | - |
| FY2018 | - | - |
As of FY2023 · SEC 10-K · Updated Feb 28, 2026